COMMUNIQUÉS West-GlobeNewswire

Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
07/07/2026
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle ™ Platform SAN DIEGO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic (OTCQB:OTLC), an AI/Robotic [...]
PDV MedTech and Corscience Announce Strategic Partnership to Advance MedTech Development and Manufacturing Across the US and Europe
07/07/2026
Collaboration connects European development expertise with U.S. manufacturing to give medtech innovators a seamless path from concept to commercialization for safety-critical medical devices. MORGAN HILL, Calif. and [...]
Luxe Treatment Center marks five years of addiction treatment in Las Vegas, surpassing 1,000 patients served
07/07/2026
Milestone arrives as Nevada remains one of the few states where overdose deaths continue to climb against the national trend. Las Vegas, NV, July 07, 2026 (GLOBE NEWSWIRE) -- Luxe Treatment Center, a licensed addiction [...]
PDV MedTech et Corscience annoncent un partenariat stratégique visant à faire progresser le développement et la fabrication de technologies médicales aux États-Unis et en Europe
07/07/2026
Cette collaboration associe l’expertise européenne en développement aux capacités de fabrication américaines afin d’offrir aux innovateurs du secteur des technologies médicales un parcours fluide, de la conception à la [...]
Applied Biologics Announces VA Federal Supply Schedule Contract Modification Supporting Long-Term Access to XWRAP®
07/07/2026
SCOTTSDALE, Ariz., July 07, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced that the [...]
Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026
07/07/2026
Phase 3 EPIDYS MRI data quantify givinostat’s potential to preserve functional muscle tissue and reduce fat infiltration in patients with Duchenne muscular dystrophy 1 Updated open-label extension data contribute to the [...]
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
07/07/2026
Investigational n.c.a. 177 Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimus Garching / Munich, July 7, 2026 – ITM Isotope Technologies [...]
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
07/07/2026
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and [...]
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
07/07/2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering [...]
HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open
07/07/2026
Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant efficacy signals in treatment-resistant depression Results support further [...]
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
07/07/2026
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company [...]
Endogenex Announces Full Enrollment of the ReCET Clinical Study
07/07/2026
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Endogenex, a [...]
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
07/07/2026
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
07/07/2026
Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to date Nearly 75% of patients reported [...]
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
07/07/2026
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
07/07/2026
In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI- [...]
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
07/07/2026
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA [...]
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
07/07/2026
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company [...]
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
07/07/2026
FDA’s PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios [...]

Pages